Biocardia reports fourth quarter and full year 2022 business highlights and financial results

Sunnyvale, calif., march 29, 2023 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended december 31, 2022 and filed its annual report on form 10-k for the year ended december 31, 2022 with the securities and exchange commission. the company will also hold an update conference call at 4:30 pm et today in which it will discuss business highlights with call details below.
BCDA Ratings Summary
BCDA Quant Ranking